What is TARGET RWE?
Founded in 2015 and based in Durham, North Carolina, TARGET RWE is at the forefront of generating and delivering real-world evidence (RWE). The company specializes in creating custom datasets, longitudinal patient registries, and regulatory-grade analyses. These services are crucial for pharmaceutical, life sciences, and healthcare partners, aiding in new drug development, label expansion, post-marketing surveillance, pharmacovigilance, and ensuring regulatory compliance across the United States and Europe. TARGET RWE's expertise spans therapeutic areas such as liver disease, gastroenterology, dermatology, and other chronic illnesses, leveraging proprietary analytics tools like causalRisk and causalPHR to derive actionable insights from comprehensive longitudinal patient journey data.
How much funding has TARGET RWE raised?
TARGET RWE has raised a total of $637K across 1 funding round:
Private Equity
$637K
Private Equity (2016): $637K, investors not publicly disclosed
What's next for TARGET RWE?
The recent major strategic investment in TARGET RWE signals a strong validation of its business model and its impact on the health evidence landscape. This capital infusion is expected to accelerate the company's growth, enabling it to enhance its data generation capabilities, expand its therapeutic focus, and broaden its reach within the pharmaceutical and life sciences industries. As TARGET RWE continues to build its enterprise-level funding, its strategic direction will likely involve further development of its advanced analytics platforms and strengthening its position as a key provider of RWE for critical healthcare decisions and regulatory submissions.
See full TARGET RWE company page
